Scholarlink

Objectives <p>This retrospective study aimed to evaluate the effect of titration-guided focal selective retina therapy (SRT) for chronic central serous chorioretinopathy (cCSCR) and determine the need and effectiveness of re-treatment.</p> Methods <p>SRT was performed in 60 eyes of 57 patients with cCSCR, targeting focal leakage points (FLP) using a Nd:YLF-Laser at 527 nm (R:GEN®, Lutronic, South Korea) titration-guided at 80% threshold, with 140 ms irradiation time, 100 Hz frequency, 1.7 µs pulse duration, 200 µm spot size. Best documented visual acuity (BDVA), peak height of subretinal fluid (SRF), height of SRF at the fovea, central retinal thickness (cRT) and total macular retinal volume (tRV) were measured.</p> Results <p>A significant improvement in BDVA was observed up to 1 year compared to baseline (<i>p</i> &lt; 0.02). A limited analysis due to the small sample size showed no significant difference between the BDVA at baseline and 2-year (<i>n</i> = 15) and 3-year (<i>n</i> = 10) follow-ups. A significant decrease in the height of the SRF at the highest point and fovea and total retinal volume up to the 3-year follow-up was observed compared to the baseline (<i>p</i> &lt; 0.03). Thirty (50%) eyes of 30 patients required re-treatment, on average 9.2 ± 9.6 months after the initial SRT. This study found no predictors for the need of re-treatment.</p> Conclusions <p>The study concludes that SRT is safe and shows anatomical and functional benefits for treating cCSCR. We recommend performing regular check-ups every three months and following a zero-fluid tolerance policy for re-treatment.</p> Trial registration <p>German Clinical Trials Register ID: DRKS00031038, registration date: 2023-01-16</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term outcomes of titration-guided focal selective retina therapy for chronic central serous chorioretinopathy: retrospective real-world data analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Migle Lindziute,
  • Maximilian Binter,
  • Nizar Al Mahamed,
  • Amelie Pielen,
  • Carsten Framme,
  • Jan Tode,
  • Marita Awe-Krüger,
  • Maximilian Binter,
  • Anke Beckmann,
  • Jan Hendrik Brahms,
  • Ralf Brinkmann,
  • Reginald Birngruber,
  • Pascal Buley,
  • Maximilian Büttner,
  • Lisa Danzmann,
  • Nicolas Feltgen,
  • Carsten Framme,
  • Marten Gehlhaar,
  • Thomas Gröber,
  • Melanie Haar,
  • Jonas Herden,
  • Hans Hoerauf,
  • Christina Sophie Jacobsen,
  • Bernd Junker,
  • Katja Kleemann,
  • Katharina Knoll,
  • Vanessa Kübler,
  • Benjamin Luger,
  • Yoko Miura,
  • Wasim Abou Moulig,
  • Migle Lindziute,
  • Ulrike Peters,
  • Amelie Pielen,
  • Johann Roider,
  • Christopher Rosenstein,
  • Eric Seifert,
  • Nina-Antonia Striebe,
  • Dirk Theisen-Kunde,
  • Jan Tode,
  • Ingo Roland Volkmann

摘要

Objectives

This retrospective study aimed to evaluate the effect of titration-guided focal selective retina therapy (SRT) for chronic central serous chorioretinopathy (cCSCR) and determine the need and effectiveness of re-treatment.

Methods

SRT was performed in 60 eyes of 57 patients with cCSCR, targeting focal leakage points (FLP) using a Nd:YLF-Laser at 527 nm (R:GEN®, Lutronic, South Korea) titration-guided at 80% threshold, with 140 ms irradiation time, 100 Hz frequency, 1.7 µs pulse duration, 200 µm spot size. Best documented visual acuity (BDVA), peak height of subretinal fluid (SRF), height of SRF at the fovea, central retinal thickness (cRT) and total macular retinal volume (tRV) were measured.

Results

A significant improvement in BDVA was observed up to 1 year compared to baseline (p < 0.02). A limited analysis due to the small sample size showed no significant difference between the BDVA at baseline and 2-year (n = 15) and 3-year (n = 10) follow-ups. A significant decrease in the height of the SRF at the highest point and fovea and total retinal volume up to the 3-year follow-up was observed compared to the baseline (p < 0.03). Thirty (50%) eyes of 30 patients required re-treatment, on average 9.2 ± 9.6 months after the initial SRT. This study found no predictors for the need of re-treatment.

Conclusions

The study concludes that SRT is safe and shows anatomical and functional benefits for treating cCSCR. We recommend performing regular check-ups every three months and following a zero-fluid tolerance policy for re-treatment.

Trial registration

German Clinical Trials Register ID: DRKS00031038, registration date: 2023-01-16